跳至主要内容
临床试验/CTRI/2021/05/033557
CTRI/2021/05/033557已完成未知

A Randomized, Double-Blind, Three-Arm, Placebo-Controlled, Comparative, Clinical Study to Evaluate the Efficacy of Nutraceutical Test Samples (As coded Test Products A, B and C) on Healthy Adult Subjects.

Patanjali Ayurved Ltd0 个研究点目标入组 52 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
52

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Age: 35 to 50 years (inclusive) at the time of consent.
  • 2.Sex: Males and Non-pregnant/Non-lactating Females (preferably equal numbers of males and females).
  • 3.Females of Childbearing potential must have a negative urine pregnancy test performed on screening visit and agree to follow an accepted method of birth control for the duration of the study.
  • 4.Corporate Subjects with complaint of feeling exhausted with routine and impaired due to lack of energy.
  • 5.Subjects with ability to understand and willingness to sign and date a written Informed Consent Document at the screening visit before any protocol- specific procedures are performed.
  • 6.Subjects willing to follow all study instructions and report to facility for all follow-up visits.

排除标准

  • 1.Subjects with acute and chronic diseases (including diabetes, inflammatory bowel diseases, dementia, multiple sclerosis).
  • 2.History of substance or alcohol abuse within the last 2 years.
  • 3.Subjects who are using additional suppliments, using medications (e.g. antihypertensive medications, lipid reducers, thyroid medication).
  • 4.Female subjects who are Pregnant or lactating women.
  • 5.Any individual who is involved with conduct of this study.
  • 6.Subjects who have participated in another study with any investigational product within 3 months of randomization.
  • 7.Subject having history of/or currently using medication which in the opinion of the investigator may affect the evaluation of the study product, or place the participant at undue risk.
  • 8.Any disease or condition that in the opinion of the investigator and/or sponsor may interfere with the completion of the study evaluation.

研究者

发起方
Patanjali Ayurved Ltd

相似试验

招募中
3 期
Clinical trial on eye health
CTRI/2023/12/060711BOTANIC HEALTHCARE PVT LTD
进行中(未招募)
1 期
A study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizuresRefractory partial-onset seizures associated with tuberous sclerosis complex (TSC)MedDRA version: 16.0Level: PTClassification code 10045138Term: Tuberous sclerosisSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2011-000860-90-GRovartis Pharma Services AG345
已完成
3 期
A three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizurestuberous sclerosis complexseizures1002766410039911
NL-OMON39634ovartis Pharma BV16
进行中(未招募)
1 期
A study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizures
EUCTR2011-000860-90-ESovartis Farmacéutica, S.A.345
进行中(未招募)
1 期
A study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizuresRefractory partial-onset seizures associated with tuberous sclerosis complex (TSC)MedDRA version: 17.0Level: PTClassification code 10045138Term: Tuberous sclerosisSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2011-000860-90-BEovartis Pharma Services AG355